Navigation Links
OncoGenex Reports Third Quarter Financial Results
Date:11/10/2008

.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements concerning agreements with the FDA regarding endpoints and clinical trial design and anticipated clinical, other product development activities and timing of these activities and the adequacy of existing financial resources. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. For example, statements of the Company's ability to gain FDA agreement on protocol design and time frames to do so, the strength of the combined oncology product pipeline, the adequacy of financial resources, the timing of clinical trials and development efforts and the results of clinical and pre-clinical studies are all forward-looking statements. The potential risks and uncertainties include, among others, the possibility that an agreement with FDA cannot be reached regarding a clinical trial using pain as the primary endpoint for OGX-011, the timing and costs of clinical trials and regulatory approvals, risks that clinical trials will not be successful or confirm earlier clinical trial results, risks associated with obtaining funding from third parties or completing a financing necessary to support the costs and expenses of clinical studies as well as research and development activities, risks relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products and the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for fiscal year 2007 and its most re
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... ... 2015 , ... Cuvettes have been used in countless labs for decades. In the past, ... needed. As expected, this was a daunting and tiring process looking at endless data ... not able to navigate the complex catalog structure. , Now thanks to FireflySci, scientists are ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... Sleepless nights ... an individual’s quality of sleep, launched its Indiegogo campaign on June 23. Sound sleepers ... voice command technology makes it effortless to use, while the integration of the Bluetooth ...
(Date:7/1/2015)... July 1, 2015   Decision Resources Group ... advantages of Otezla are its oral administration, alternative ... reported by surveyed rheumatologists. Otezla was the first ... treatment of active psoriatic arthritis in ... of care includes conventional oral treatments including disease-modifying ...
(Date:7/1/2015)... , July 1, 2015  Axovant Sciences ... focused on the treatment of dementia, today announced ... on July 22 at 5:45 p.m. EDT following ... Alzheimer,s Association International Conference 2015 (AAIC). ... , Dr. Lawrence Friedhoff , ...
Breaking Biology Technology:New Cuvette E-Commerce Website Launched by FireflySci 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3
... there, time to listen up. Heres something new to ... international survey research and consulting firm, estimates that actively ... year in productivity losses! The Gallup Management Journal's ... of employees who are actively disengaged at 17%. Thats ...
... MADISON The University of Wisconsin-Madison has launched a new ... university happenings. , ,UWs Office of Corporate Relations and University ... service, which includes news stories, upcoming events and links to ... , ,We wanted to collect in one place ... all ...
... Childrens Hospital of Wisconsin is helping to ... freezing the tissue causing the abnormality. , ,A special ... temperatures as low as minus 80 degrees Celsius inside ... Hospital, an electrophysiologist and pediatric cardiologist guide the catheter ...
Cached Biology Technology:The high cost of employee disengagement 2The high cost of employee disengagement 3Wire service to connect UW-Madison to business 2
(Date:6/30/2015)... 2015 To bolster its efforts and commitment to ... today the addition of two new team members. ... and David Raviv will act as head of ... commitment to providing the most secure solutions for the enterprise ... Layer 7 Technologies, a provider of security and management products, ...
(Date:6/25/2015)... DALLAS , June 25, 2015 ... report "Fingerprint Sensors Market by Type (Swipe & Area), Technology, ... (Mobile, Government, Healthcare, Commercial Security & Others) & ... published by marketsandmarkets, the said market is expected ... CAGR of 17.1%. Browse 76 ...
(Date:6/24/2015)... 2015 This report provides market analysis of ... years. It contains an analysis of the drivers, challenges, ... impact from the short, medium, and long term perspective ... market, and technology trends that currently, prevail in the ... authorities to efficiently manage the increasing marine traffic and ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2
... Even if you eat right and exercise regularly, chances are ... stroke. But thanks to new findings by researchers from Harvard ... Two unrelated studies recently published online in The ... atherosclerosis that have the potential to save millions of lives. ...
... fish, seabirds, and other marine animals are routinely killed ... Known as marine bycatch, this problem is an ongoing ... One recent proposal would compensate for bycatch by reducing ... suggests that this strategy could end up doing more ...
... curious about Earth,s periodic mass extinction events such as the ... might consider crashing asteroids and sky-darkening super volcanoes as culprits. ... the journal Nature , suggests that it is the ... sea level and sediment over the course of geologic time, ...
Cached Biology News:New discoveries from Harvard and Baylor get to the heart of cardiovascular disease 2New discoveries from Harvard and Baylor get to the heart of cardiovascular disease 3New study raises concerns about proposed mitigation strategy for marine bycatch 2The mystery of mass extinctions is no longer murky 2The mystery of mass extinctions is no longer murky 3
... manual data entry by collecting data from ... application. Collect is extremely easy to ... tedious data entry. An excellent solution ... meters, spectrophotometers, force gauges, digital calipers, bar ...
... the autofluorescent pigment lipofuscin accumulates in ... including neurons. The presence of lipofuscin ... fluorescence microscopy in the central nervous ... and emission spectra, which overlaps with ...
DNA sequencing - plasmids or PCR fragments, 3-7 working days service....
Polyclonal Antibody to Golgin-67...
Biology Products: